Huadong Medicine Co., Ltd (SHE:000963)
China · Delayed Price · Currency is CNY 33.75
-0.46 (-1.34%)
Apr 28, 2026, 3:04 PM CST
Huadong Medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 43,655 | 43,208 | 41,508 | 40,261 | 37,489 | 34,418 |
Other Revenue | 404.2 | 404.2 | 397.3 | 362.43 | 226 | 145.56 |
| 44,060 | 43,612 | 41,906 | 40,624 | 37,715 | 34,563 | |
Revenue Growth (YoY) | 4.33% | 4.07% | 3.16% | 7.71% | 9.12% | 2.61% |
Cost of Revenue | 29,690 | 29,509 | 28,006 | 27,468 | 25,686 | 23,969 |
Gross Profit | 14,370 | 14,103 | 13,899 | 13,156 | 12,028 | 10,595 |
Selling, General & Admin | 8,237 | 7,871 | 7,806 | 8,066 | 7,584 | 6,591 |
Research & Development | 1,588 | 1,753 | 1,426 | 1,271 | 1,016 | 979.64 |
Other Operating Expenses | 294.68 | 219.42 | 214.72 | 203.41 | 205.31 | 176.11 |
Operating Expenses | 10,257 | 9,980 | 9,558 | 9,566 | 8,873 | 7,788 |
Operating Income | 4,113 | 4,122 | 4,341 | 3,590 | 3,155 | 2,806 |
Interest Expense | -77.02 | -83.77 | -96.95 | -114.91 | -120.04 | -68.48 |
Interest & Investment Income | 74.86 | 82.52 | 104 | 94.05 | 103.35 | 80.4 |
Currency Exchange Gain (Loss) | 13.94 | 13.94 | -2.56 | -1.04 | -34.7 | -2.27 |
Other Non Operating Income (Expenses) | 8.26 | -31.46 | -130.59 | -29.65 | -27.16 | -31.93 |
EBT Excluding Unusual Items | 4,133 | 4,104 | 4,215 | 3,538 | 3,076 | 2,784 |
Impairment of Goodwill | -78.11 | -78.11 | - | - | - | -2.92 |
Gain (Loss) on Sale of Investments | -117.53 | -137.84 | -129.19 | -233.47 | -113.09 | -96.31 |
Gain (Loss) on Sale of Assets | 17.34 | 2.26 | -5.46 | 4.32 | 8.26 | -0.03 |
Asset Writedown | -3.32 | -3.32 | -25.19 | -5.14 | -5.87 | -5.09 |
Other Unusual Items | 152.26 | 129.92 | 246.61 | 161.87 | 65.6 | 147.89 |
Pretax Income | 4,104 | 4,016 | 4,302 | 3,466 | 3,031 | 2,828 |
Income Tax Expense | 609.68 | 605.62 | 807.33 | 619.59 | 498.5 | 488.91 |
Earnings From Continuing Operations | 3,494 | 3,411 | 3,494 | 2,846 | 2,533 | 2,339 |
Minority Interest in Earnings | 7.79 | 3.49 | 17.92 | -7.54 | -33.41 | -37 |
Net Income | 3,502 | 3,414 | 3,512 | 2,839 | 2,499 | 2,302 |
Net Income to Common | 3,502 | 3,414 | 3,512 | 2,839 | 2,499 | 2,302 |
Net Income Growth | -1.76% | -2.78% | 23.71% | 13.59% | 8.58% | -18.38% |
Shares Outstanding (Basic) | 1,753 | 1,752 | 1,752 | 1,750 | 1,750 | 1,750 |
Shares Outstanding (Diluted) | 1,754 | 1,754 | 1,753 | 1,752 | 1,750 | 1,750 |
Shares Change (YoY) | -0.02% | 0.06% | 0.08% | 0.10% | 0.00% | -0.00% |
EPS (Basic) | 2.00 | 1.95 | 2.00 | 1.62 | 1.43 | 1.32 |
EPS (Diluted) | 2.00 | 1.95 | 2.00 | 1.62 | 1.43 | 1.32 |
EPS Growth | -1.73% | -2.84% | 23.61% | 13.47% | 8.58% | -18.37% |
Free Cash Flow | 3,027 | 2,671 | 2,021 | 2,323 | 1,189 | 2,351 |
Free Cash Flow Per Share | 1.73 | 1.52 | 1.15 | 1.33 | 0.68 | 1.34 |
Dividend Per Share | 0.930 | 0.930 | 0.930 | 0.580 | 0.290 | 0.290 |
Dividend Growth | - | - | 60.35% | 100.00% | - | 26.09% |
Gross Margin | 32.61% | 32.34% | 33.17% | 32.38% | 31.89% | 30.65% |
Operating Margin | 9.34% | 9.45% | 10.36% | 8.84% | 8.37% | 8.12% |
Profit Margin | 7.95% | 7.83% | 8.38% | 6.99% | 6.63% | 6.66% |
Free Cash Flow Margin | 6.87% | 6.13% | 4.82% | 5.72% | 3.15% | 6.80% |
EBITDA | 5,076 | 5,045 | 5,105 | 4,318 | 3,778 | 3,316 |
EBITDA Margin | 11.52% | 11.57% | 12.18% | 10.63% | 10.02% | 9.59% |
D&A For EBITDA | 962.57 | 922.92 | 764.35 | 727.64 | 622.73 | 509.65 |
EBIT | 4,113 | 4,122 | 4,341 | 3,590 | 3,155 | 2,806 |
EBIT Margin | 9.34% | 9.45% | 10.36% | 8.84% | 8.37% | 8.12% |
Effective Tax Rate | 14.86% | 15.08% | 18.77% | 17.88% | 16.45% | 17.29% |
Revenue as Reported | 44,060 | 43,612 | 41,906 | 40,624 | 37,715 | 34,563 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.